Clinical trial

Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism

NCT02721888

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Liraglutide Normalized identity: liraglutideView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy) Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention Blood sample Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention Kinetic substudy (10 patients) Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE4

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2012-07-10

PhasePHASE4

Conditions

Type 2 Diabetesverified · MONDO: type 2 diabetes mellitus

Interventions

LiraglutideDRUG · verified · RxNorm: liraglutide

MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)DRUG

Blood sampleBIOLOGICAL

Kinetic substudy (10 patients)OTHER

Sponsors & collaborators

Centre Hospitalier Universitaire Dijonlead sponsor

Mapped research locations

DijonFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02721888 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.